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Investigation of the role of tyrosine
kinase receptor EPHA3 in colorectal
cancer
Elena Andretta1, Fernando Cartón-García1, Águeda Martínez-Barriocanal1,
Priscila Guimarães de Marcondes1, Lizbeth M. Jimenez-Flores1, Irati Macaya1,
Sarah Bazzocco1, Josipa Bilic1, Paulo Rodrigues1, Rocio Nieto1, Stefania Landolfi2,
Santiago Ramon y Cajal2, Simo Schwartz Jr.3,4, Arthur Brown5, Higinio Dopeso1 &
Diego Arango1
EPH signaling deregulation has been shown to be important for colorectal carcinogenesis and genomewide sequencing efforts have identified EPHA3 as one of the most frequently mutated genes in these
tumors. However, the role of EPHA3 in colorectal cancer has not been thoroughly investigated. We
show here that ectopic expression of wild type EPHA3 in colon cancer cells did not affect their growth,
motility/invasion or metastatic potential in vivo. Moreover, overexpression of mutant EPHA3 or
deletion of the endogenous mutant EPHA3 in colon cancer cells did not affect their growth or motility.
EPHA3 inactivation in mice did not initiate the tumorigenic process in their intestine, and had no effects
on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. In addition,
immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or
clinicopathological features of colorectal cancer patients. In conclusion, we show that EPHA3 does not
play a major role in colorectal tumorigenesis. These results significantly contribute to our understanding
of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed
functional studies to confirm the relevance of putative cancer driver genes identified in sequencing
efforts of the cancer genome.
Since the first EPH receptor was cloned over 25 years ago1 this family has expanded and become the largest family
of receptor tyrosine kinases, with at least 9 type A and 5 type B EPH receptors. EPH receptors are classified into
the A and B subclass depending on sequence similarity and the type of Ephrin ligands that they bind2. Ephrin A
and B ligands are anchored to the plasma membrane either through a glycosyl-phosphatidylinositol (GPI) moiety,
or a transmembrane domain, respectively. These receptors and their Ephrin ligands are important for recognizing
signals from the extracellular environment and are involved in cell-cell interaction, participating in cell adhesion, migration and proliferation, both during embryogenesis and in adult tissues2–4. In the normal intestinal
epithelium, EPHB2 and EPHB3 have a key role in maintaining spatially separate proliferative and differentiating
compartments5,6. Moreover, abrogation of EPHB2 and EPHB3 signaling reduces the number of proliferating cells
in intestinal crypts by >50%7.
Deregulation of EPH signaling has been shown to be important for tumor progression in different organs,
including colorectal tumors2. The loss of EPHB2, EPHB3 and EPHB4 significantly contributes to the early stages
of the tumorigenic process8–11. Despite the documented relevance of the inactivation of these EPH receptors on
the oncogenic process of colorectal tumors, genome-wide sequencing efforts did not identify recurrent mutations
in these receptors or in their ligands12–15. Surprisingly, however, EPHA3 was identified in early genome-wide
sequencing studies in colorectal tumors14 as the sixth most frequently mutated gene with mutations in >11% of
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the tumors and a cancer mutation prevalence (CaMP) score >4. Only APC, TP53, KRAS, FBXW7 and SMAD4
showed CaMP scores higher than EPHA3 and the mutation frequency in this EPH receptor was higher than
the incidence observed in other known tumor suppressor genes in this organ, such as SMAD2 and TGFBR214.
Moreover, additional studies have confirmed the presence of recurrent EPHA3 mutations in colorectal tumors12,13
that are distributed throughout the coding sequence of EPHA3 (Supplementary Figure 1) and that have been
shown to disrupt EPHA3 signaling16. Based on these genetic data, and the known importance of EPH signaling
in colorectal cancer, EPHA3 inactivation would be expected to significantly contribute to the progression of
colorectal tumors. However, the role of EPHA3 in the oncogenic process of this organ has not been investigated.
Here we used inducible isogenic cell line systems, animal models and large human tumor collections to investigate the role of EPHA3 during colorectal cancer progression. Despite the evidence from the genetic screens, we
found that overexpression of wild type or mutant EPHA3 did not affect the growth of colon cancer cells. In addition, targeted inactivation of EphA3 in mice did not initiate the tumorigenic process in the intestinal epithelium,
and when tumors were initiated genetically or pharmacologically, EphA3 inactivation had no effects on animal
survival, tumor size or multiplicity. Moreover, reintroduction of EPHA3 in colon cancer cells did not change
their motility/invasion in vitro or their metastatic potential in a mouse model of experimental metastasis. Finally,
immunohistochemical analysis revealed that the levels of EPHA3 expression in colorectal tumors were not associated with any clinicopathological features or with patient survival. Collectively, our results indicate that EPHA3
inactivation is not an important step in the tumorigenic process of colorectal tumors, and highlights the need to
functionally validate the findings of large exome/genome sequencing studies.

Results

Generation of colon cancer cell lines with inducible EPHA3 activity. Several EPH receptors and
their Ephrin ligands have been found to be aberrantly expressed in multiple cancer types and to significantly
contribute to the oncogenic process of colorectal tumors8,11,17. To investigate the functional role of EPHA3 in
colorectal cancer, we engineered two cell line systems with doxycycline-dependent inducible EPHA3 expression.
LS174T and DLD1 colon cancer cell lines were used because they express low endogenous levels of wild type or
compound heterozygous mutant (T719I and M847K) EPHA3 protein18, respectively (Supplementary Figure 2A),
and high levels of the preferred EPHA3 ligand EphrinA5 (Supplementary Figure 2B). These cell lines were
stably transfected with a vector expressing wild type human EPHA3 under the control of the doxycycline-inducible CMV/TO promoter (pLenti-CMV/TO-EPHA3) or the corresponding control empty vector. Doxycyclinedependent expression of EPHA3 was confirmed on individual clones by Western blot (Fig. 1A,B) and membrane
localization was assessed by flow cytometry analysis (Fig. 1C,D). Moreover, phosphorylation of the EPHA3 receptor upon doxycycline treatment was confirmed by an immunoprecipitation assay, thus confirming activation of
the EPHA3 signaling pathway in these cells (Fig. 1E,F).
EPHA3 does not regulate the growth of colon cancer cells. EPH signaling has been shown to be
important to sustain the active proliferation rates found in the intestinal epithelial cells and in intestinal tumors8–11. Here we used the cell line systems generated to study whether EPHA3 signaling regulates the proliferative activity of colon cancer cells. First, we investigated whether the reintroduction of EPHA3 into LS174T and
DLD1 colon cancer cells modulated their growth in vitro by directly counting the number of cells at different
times post-seeding, and found no differences after EPHA3 overexpression by doxycycline treatment (Fig. 2A,B).
Moreover, ectopic expression of wild type EPHA3 did not affect the capacity of colon cancer cells to form colonies when growing on a solid or a semisolid soft-agar substrate (Fig. 2C,D). The effects of EPHA3 on the growth
of colon cancer cells were further investigated using a xenograft model. LS174T-EPHA3 or control LS174T-EV
were injected subcutaneously in the right and left flank of NOD/SCID immunodeficient mice, respectively.
Animals were then randomized to receive doxycycline in the drinking water or a control group, and xenograft growth was monitored over time. The same experimental layout was carried out with the DLD1-EPHA3
derivative lines. No differences were observed in the average size of the xenografts formed by these cell lines in
animals treated with doxycycline compared to untreated control mice (Fig. 2E,F). EPHA3 overexpression was
confirmed by immunohistochemistry at the end of the experiment in the tumors from doxycycline-treated mice
(Supplementary Figure 3). Collectively, these results show that the reintroduction of EPHA3 into deficient colon
cancer cells does not affect their growth.
Characterization of the role of Epha3 in intestinal tumorigenesis using a knockout mouse
model. Because other EPH receptors have been shown to be involved in the oncogenic process of intesti-

nal tumors using mouse models8,11, we next decided to investigate the role of this Eph receptor in vivo using a
knockout mouse model where the first exon of EphA3 has been deleted by homologous recombination19. We
confirmed loss of expression in the intestine and liver of Epha3 KO mice by quantitative real-time RT-PCR
(Supplementary Figure 4). As previously reported, we observed perinatal mortality of approximately two thirds
of the EphA3−/− mice due to cardiac defects, although the remaining 34% of the knockout mice were viable with
no obvious cardiac phenotype or any other abnormalities19,20.
Importantly, we found that the loss of Epha3 does not affect adult animal survival (Supplementary Figure 5) or
the incidence of intestinal tumors at 20 months of age (Fig. 3A,B), indicating that the loss of Epha3 does not promote tumor initiation. Intestinal tumorigenesis was therefore initiated genetically by crossing the EphA3 model
with Apcmin/+ mice carrying heterozygous mutations in the Apc tumor suppressor gene21. We observed that the
lifespan of Apcmin/+ mice was not affected by the loss of one or two copies of EphA3 (Fig. 3C). In good agreement
with this finding, the number, size or histological type of intestinal tumors at 41 weeks of age was not different in
Apcmin/+ mice that are either wild type, heterozygous or homozygous for the EphA3 knockout allele (Fig. 3D–G).
The majority of the intestinal tumors observed were adenomas (54 of 83; 65.1%). Some adenocarcinomas that
SCIENTIfIC REPOrTS | 7:41576 | DOI: 10.1038/srep41576
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Figure 1. Inducible EPHA3 overexpression in colon cancer cell lines. (A,B) Western blot showing the
levels of EPHA3 protein in LS174T (A) and DLD1 (B) cells stably transfected with pLenti/TO-EPHA3 or
the control empty vector (EV) after treatment with the indicated concentrations of doxycycline for 48 h.
Tubulin levels are shown as a loading control. (C,D) Cell surface levels of EPHA3 following induction with
doxycycline (1 μg/ml; 48 h) were assessed by flow cytometry analysis in LS174T-EPHA3 (C) and DLD1EPHA3 (D). (E,F) The levels of EPHA3 phosphorylation after doxycycline treatment (1 μg/ml) for 48 h were
determined by immunoprecipitation with anti-EPHA3 and Western blotting with anti-phospho-Tyrosine.
Total input levels of EPHA3 and tubulin are also shown for LS174T-EPHA3 (E) and DLD1-EPHA3 (F).

invaded through the mucosa (20.5%), submucosa (4.8%) or the muscularis propria (6.0%) were also observed.
In addition, intestinal tumorigenesis was induced pharmacologically in an independent cohort of mice with the
intestinal-specific carcinogen azoxymethane (AOM). However, consistent with the findings of the Apcmin/+ model,
no differences were observed in the number, size or histology of large intestinal tumors in EphA3 wild type and
knockout mice (Fig. 3H,I). Most tumors found were adenomas (25 of 36; 69.4%). Some adenocarcinomas infiltrating the mucosa (25.0%) or the submucosa (5.6%) were also observed in the large intestine, while no tumors
were found in the small intestine of AOM-treated mice. Overall, these experiments indicate that, unlike the loss of
EphB receptors, EphA3 inactivation does not significantly contribute to intestinal tumor initiation or progression
during the early stages of the tumorigenic process in murine models.

Reintroduction of EPHA3 into deficient colon cancer cells does not affect their metastatic
potential. Although our results with the EphA3 knockout mouse model indicate that the loss of EphA3 is not

an important event in the early stages of tumor development, it remained possible that EPHA3 may be involved
in the metastatic process of colon cancer cells. Because EPHA3 has been shown before to regulate cell adhesion
and migration in other tumor types22,23, we first investigated the effects of reintroducing wild type EPHA3 on
the motility/migration capacity of colon cancer cells. A wound-healing assay demonstrated that EPHA3 overexpression did not change the motility of LS174T and DLD1 cells (Fig. 4A–D). Next, we investigated whether
restoration of EPHA3 signaling affected the invasive potential of colon cancer cells. A Boyden chamber assay
demonstrated that EPHA3 activation in LS174T and DLD1 cells did not affect the capacity of these cells to invade
SCIENTIfIC REPOrTS | 7:41576 | DOI: 10.1038/srep41576
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Figure 2. Effects of EPHA3 overexpression on the growth of colon cancer cells. (A,B) The average number
of LS174T-EPHA3 (A) and DLD1-EPHA3 (B) cells and the corresponding empty vector control (EV) at the
indicated times after seeding is shown (mean ± SEM of three independent experiments). (C,D) Number of
colonies of LS174T-EPHA3 (C) and DLD1-EPHA3 (D) cells and the corresponding empty vector control (EV)
grown on a solid plastic substrate (left), or on soft agar (right) with or without doxycycline treatment
(1 μg/ml). The mean ( ±SEM) of three independent experiments run in triplicate is shown. (E,F) Growth of
LS174T-EPHA3 (E) and DLD1-EPHA3 (F) cells when injected subcutaneously in immunodeficient
NOD/SCID mice. Doxycycline was administered to the indicated groups of animals in the drinking water.
The average tumor size ( ±SEM) is shown. N = 6 animals per group.
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Figure 3. Effects of targeted inactivation of Epha3 on mouse intestinal tumorigenesis. (A,B) Histograms
showing the number (A) and size (B) of intestinal tumors in EphA3 wild type and knockout mice at the age
of 20 months. (C) Survival of Apcmin/+ mice that are either wild type, heterozygous or homozygous for EphA3
inactivation (n = 20 animals per group). (D) Representative histological image of the normal small intestine,
and (E) a representative small intestinal tumor. Samples were stained with hematoxylin and eosin. Scale bar
100 μm. (F,G) Number (F) and size (G) of small intestinal tumors observed in 41-week-old Apcmin/+ mice that
are either wild type, heterozygous or homozygous for EphA3 inactivation. (I,J) Number (I) and size (J) of large
intestinal tumors observed in 25-week-old wild type or EphA3 knockout mice after azoxymethane (AOM)
treatment. N = number of animals per group. All histograms show average values ± SEM. All p-values shown
were calculated using Student’s T-test.
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Figure 4. Effects of EPHA3 on colon cancer cell motility and invasion. (A–D) Changes in the motility of
LS174T (A and C) and DLD1 (B and D) cells after EPHA3 overexpression were assessed using a wound healing
assay. Cells transfected with the control empty vector (EV) were used along with cells expressing EPHA3
after doxycycline (Dox) treatment (1 μg/ml). Panels (A,B) show representative images and panels (C,D) show
the average ( ±SEM) percentage of the initial wound closed after the indicated times in three independent
experiments carried out in triplicate. (E,F) Matrigel Invasion capacity (Boyden chamber invasion assay) of
LS174T-EPHA3 (E) and DLD1-EPHA3 (F) with and without doxycycline (Dox)-dependent induction of
EPHA3 overexpression. The corresponding empty vector (EV) derivative lines were used to control for possible
effects of doxycycline on the invasion of these cells. The average ( ±SEM) of three independent experiments
carried out in triplicate is shown.
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Figure 5. Effects of EPHA3 overexpression on the metastatic potential of colon cancer cells. (A) Average
number ( ±SEM) of macroscopically visible metastases formed by LS174T-EPHA3 or DLD1-EPHA3 cells 6 or
10 weeks, respectively, after tail vein injection in NOD/SCID immunodeficient animals receiving doxycycline
(Dox) in the drinking water or control animals. N = number of animals. (B) Representative images of
hematoxylin and eosin stained histological lung sections of the mice in. N: normal; T: tumor. Scale bar: 100 μm.

through matrigel (Fig. 4E,F). We then used an experimental model of lung metastasis where LS174T-EPHA3 or
DLD1-EPHA3 cells were injected in immunodeficient NOD/SCID mice that were then randomized to a control group or a group receiving doxycycline in the drinking water to induce EPHA3 expression. No differences
were observed in the number of lung metastases formed by LS174T or DLD1 cells after EPHA3 overexpression
(Fig. 5A). The presence of metastatic lesions in the lungs of these animals was confirmed on histological sections
(Fig. 5B). When considered together these results demonstrate that the reintroduction of EPHA3 in colon cancer
cells does not interfere with their metastatic potential.

EPHA3 mutations do not affect proliferation or motility of colon cancer cells.

Collectively,
our results indicate that wild type EPHA3 does not regulate the growth or metastasis of colorectal tumors. We
next investigated whether the EPHA3 mutations frequently observed in colorectal tumors are oncogenic. First,
we used a doxycycline-dependent inducible system to overexpress EPHA3D806N in DLD1 and LS174T colon
cancer cells (Supplementary Figure 6A–D). This mutation has been observed in skin and colon tumors14,24
and codes for a stable protein that lacks kinase activity16,25,26. In addition, we used a CRISPR/Cas9 approach
to knockout the endogenous compound heterozygous mutant EPHA3 in SW48 cells (K365Nfs*6 and G784E;
Supplementary Figure 2A)18,27. Cells were transiently transfected with a vector expressing Cas9/GFP and a guiding RNA targeting the first exon of EPHA3. Three individual clones derived from GFP-positive cells were amplified and the presence of truncating mutations confirmed by direct sequencing and the loss of EPHA3 protein
confirmed by Western blot (Supplementary Figure 6E,F). Three additional clones showing no EPHA3 mutations
were used as control (Supplementary Figure 6E,F). Overexpression of the EPHA3D806N mutant protein in DLD1
or LS174T cells, or deletion of the endogenous mutant EPHA3 in SW48 cells had no effect on cell proliferation
(Fig. 6A–C) or motility (Fig. 6D–F), indicating that these EPHA3 mutations observed in colon tumors do not
confer a growth/motility advantage.

Survival of colorectal cancer patients as a function of EPHA3 tumor levels. An association has
been observed between EPHA3 levels and the survival of patients with different tumor types, including colorectal cancer25,28–31. Here, we used a tissue microarray containing triplicate tumor samples from 159 patients with
Dukes C colorectal cancer to investigate possible associations between EPHA3 levels and survival of colorectal
cancer patients (Supplementary Table 1). The levels of EPHA3 protein expression in these tumors were determined by immunohistochemistry and the specificity of the antibody used was confirmed on formalin-fixed,
paraffin-embedded samples from the xenografts generated with the cell lines engineered to overexpress EPHA3
(Supplementary Figure 3). Tumor samples showed variable levels of EPHA3 expression that ranged from undetectable to high expression (Fig. 7A,B). However, no associations were observed between EPHA3 expression and
disease-free or overall survival (Logrank test p > 0.39; Fig. 7C,D) and other clinicopathological features including
patient age, gender, tumor location and histological grade (Supplementary Table 1). In addition, for 16 of these
primary Dukes C tumors, the paired lymph node metastasis from the same patient was also available. Consistent
with our in vitro data and the model of experimental metastasis, no significant differences in the levels of EPHA3
were observed between matched primary and metastatic lesions (Fig. 7E), further indicating that EPHA3 does
not regulate the metastatic dissemination of colon cancer cells.
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Figure 6. Effects of the modulation of mutant EPHA3 expression on proliferation and motility of colon
cancer cells. Doxycycline-dependent overexpression of mutant EPHA3D806N in DLD1 cells (A,D) and LS174T
cells (B,E) or targeted deletion of the endogenous mutant EPHA3 in SW48 cells (D,F), did not affect cell growth
(sulforhodamine B staining; A–C) or motility (wound healing assay; D–F). The average (±SEM) of three
independent experiments carried out in triplicate is shown.

Discussion

EPH signaling has been shown to regulate the proliferative activity in the normal intestinal epithelium and maintain proliferating cells confined to the crypts of Lieberkühn7,32. In addition, disruption of EPH signaling has
been reported to significantly contribute to the progression of colorectal cancer. We have previously reported
frequent (>40%) EPHB2 mutations in colorectal tumors with microsatellite instability10, and targeted inactivation of both alleles of EphB2 or EphB3, or a single allele of EphB4, significantly accelerate the tumorigenic process
initiated by Apc mutations in mouse models8,33. Moreover, the expression of several EPH receptors, including
EPHB2, EPHB3, EPHB4 or EPHA2 are associated with the prognosis of patients with colorectal cancer9,32–36.
Pioneer genome-wide exome sequencing studies reported that 11.4% (4/35) of colorectal tumors had mutations
in EPHA314 and these mutations have been reported to disrupt the function of EPHA316, suggesting that they
contribute to tumor progression. However, significantly lower EPHA3 mutation frequency was observed in an
extended cohort of colorectal tumors (4.05%; 42/1035)37–39. Interestingly, in lung cancer, where EPHA3 has been
shown to have tumor suppressor activity25, the reported mutation frequency is over 9% (105/1144)40.
Here, we show that reintroduction of this EPH receptor into colon cancer cells with low levels of either wild
type (LS174T) or mutant (DLD1) EPHA3 and that express the preferred EPHA3 ligand (Ephrin A5), has no
effects on the growth of cancer cells on a solid substrate, soft agar or when grown as subcutaneous xenografts
in immunodeficient NOD/SCID mice. Consistently, we used a mouse model with targeted EphA3 inactivation
and demonstrated that the loss of EphA3 did not initiate the tumorigenic process in the intestine, and had no
effects on the tumorigenic process initiated by heterozygous Apc mutations (Apcmin/+ mice) or pharmacologically
with the intestine-specific carcinogen azoxymethane (AOM). Therefore, despite the reported role of type B EPH
SCIENTIfIC REPOrTS | 7:41576 | DOI: 10.1038/srep41576
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Figure 7. Survival of colorectal cancer patients with high and low EPHA3 levels in their tumors.
The levels of EPHA3 protein were assessed by immunohistochemistry with a specific antibody (see
Supplementary Figure 3) in normal colonic mucosa (A) and colorectal tumors (B). Disease-free (C) and overall
survival (D) of 159 Dukes C colorectal cancer patients as a function of tumor EPHA3 levels was studied. P
values are from the Logrank test. (E) Average protein expression levels in 16 paired primary Dukes C tumors
and lymph node metastases from the same patients (p value shown is from a paired Student’s T-test).
receptors in the progression of colorectal cancer and the high frequency of EPHA3 mutations observed in early
genome-wide mutatome analyses, our results indicate that modulation of EPHA3 signaling does not regulate the
growth of intestinal cancer cells.
The intestinal tumors observed in the Apcmin/+ and AOM animal models used do not metastasize and are
therefore not ideally suited to investigate the role of EPHA3 on the metastatic dissemination of colorectal cancer
cells. However, EPHA3 has been shown to regulate the attachment of melanoma cancer cells23 and is associated
with metastatic dissemination in hepatocellular carcinoma29. Moreover, EPHA3 has been suggested to regulate
the metastatic spread of colorectal tumors to lymph nodes and distant organs31,41. We therefore decided to further investigate the role of EPHA3 in the invasive and metastatic potential of colorectal tumors and found that
reintroduction of EPHA3 in colon cancer cells had no effect on their motility/invasion in vitro. Consistently,
reintroduction of EPHA3 in colon cancer cells did not affect their metastatic potential in an experimental model
of lung metastasis and no differences were observed in the expression of EPHA3 in primary Dukes C tumors and
matched lymph node metastases, indicating that EPHA3 does not play a major role in the metastatic process of
these tumors. These results suggest that the role of EPHA3 on the metastatic potential of cancer cells is context
dependent, contributing to disease dissemination in some tumor types such as melanoma or hepatocellular carcinoma23,29, while having no significant effect in colorectal tumors.
Our results indicate that restauration of EPHA3 expression in colon cancer cells with low/undetectable
EPHA3 levels, or EphA3 deletion in mouse models of intestinal tumorigenesis, does not alter the phenotype
of these tumor cells. However, several EPH receptors have been shown to have tumor promoting or inhibitory
activity in the same tumor type depending on the levels of activation of EPHA3 signaling42–44. EPHA3 has recently
been shown to be highly expressed in glioblastoma, where it remains kinase-dormant due to reduced or absent
Ephrin ligand expression, and plays an important role maintaining glioblastoma cells in an undifferentiated state
and sustains rapid proliferation28. However, either EPHA3 knockdown or EPHA3 kinase activation through
binding to Ephrin A5 or an agonist antibody, resulted in a significant reduction of the growth of glioblastoma
cells28, suggesting that in these tumors EPHA3 has ligand/kinase-independent oncogenic activity and ligand/
kinase-dependent tumor suppressor activity. In colorectal tumors, the mutations observed in EPHA3 have been
shown to disrupt its ligand binding capacity or its kinase activity16. However, these mutations could result in a
SCIENTIfIC REPOrTS | 7:41576 | DOI: 10.1038/srep41576
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gain of function of EPHA3 or preserve kinase-independent oncogenic activity. To investigate this possibility, we
overexpressed mutant EPHA3D806N in DLD1 and LS174T colon cancer cells with low endogenous EPHA3 expression, or used a CRISPR/Cas9 strategy to knockout the mutant EPHA3 expressed at high levels in SW48 cells.
However, we observed no changes in the motility or proliferation in these isogenic cell line systems, suggesting
that in colon cancer cells EPHA3 mutations are not oncogenic. These results seem at odds with recent data suggesting that wild type, as well as mutant EPHA3 may have oncogenic activity in colon epithelial cells41. However,
a single mouse cell line model was used in this study by Li and collaborators41, and further investigation will be
required to clarify the role of EPHA3 in the earlier steps of the oncogenic process.
EPHA3 tumor levels have been reported to be associated with the survival of patients with different cancer types, including hepatocellular carcinoma29, gastric30 and lung45 cancer. Interestingly, high EPHA3 protein
levels assessed by immunohistochemistry in colorectal tumors have been reported to be associated with poor
prognosis of colorectal cancer patients as well as other clinicopathological features of these tumors31,41. Here, we
assessed the levels of EPHA3 in the tumors of a cohort of 159 patients with locally advanced (Dukes C) colorectal
cancer by immunohistochemistry with a rabbit polyclonal antibody that specifically detects human EPHA3 on
formalin-fixed, paraffin embedded samples (Supplementary Figure 3). Our analysis did not find any associations
between EPHA3 tumor levels and disease-free survival, overall survival or any clinicopathological features of
Dukes C colorectal cancer patients. This apparent discrepancy could be due to the use of different antibodies to
detect EPAH3 in different studies. Alternatively, EPHA3 levels could be associated with tumor stage, as suggested
by Xi and Zhao31, but have no prognostic value when the analysis is restricted to patients with the same disease
stage.
In conclusion, we have investigated here the functional role of EPHA3 on the oncogenic process of colorectal
cancer. Although EPHA3 was reported to be one of the most frequently mutated genes in colorectal tumors, our
studies using inducible isogenic cell line systems, mouse models and large human tumor collections, did not
reveal a major role of this EPH receptor on proliferation/motility/invasion of cancer cells, tumor initiation/progression/metastasis in mouse models or survival of colorectal cancer patients. This could be due to high levels of
redundancy between EPH receptors in colorrectal tumors. Alternatively, EPHA3 mutations may affect the tumor
phenotype in aspects not directly investigated in this study, such as angiogenesis, the immune response of the
host or growth under starvation/hypoxic conditions. These results represent an important contribution to our
understanding of the role of EPH signaling during colorectal carcinogenesis, and underscore the need for functional studies in vitro and in vivo to confirm the relevance of putative cancer driver genes identified in sequencing
efforts of the cancer genome.

Material and Methods

Cell Lines. DLD1 and LS174T colon cancer cell lines were cultured on RPMI medium with 10% fetal bovine
serum (Sigma) and 1x antibiotic antimycotic (Life Technologies) at 37 °C and 5% CO2. LS174T (EPHA3 wild
type) and DLD1 (heterozygous EPHA3 T719I and M847K mutations) cells carrying the tet-repressor plasmid
(TR1 and TR7, respectively) were generated using the T-rex system (Invitrogen) as described previously46. To
generate EPHA3-inducible clones, DLD1-TR7 and LS174T-TR1 expressing the Tet repressor were transfected
with pLenti-CMV/TO-EPHA3 and the corresponding empty vector (pLenti-CMV/TO Neo DEST, Addgene
#17292) with Lipofectamine 2000. Transfectants were selected in medium containing G418 (1 or 0.5 mg/ml for
DLD1 and LS174T respectively; Invitrogen). Resistant clones were picked and expanded. After doxycycline treatment (1 μg/ml; Sigma) for 48 h, the overexpression of EPHA3 was tested by FACS and western blot. EPHA3D806N
was conditionally overexpressed in parental DLD1 and LS174T cells after lentiviral transduction with pINDUCER20-EPHA3D806N or control pINDUCER20-GFP47. Viral supernatants obtained from HEK293 cells were applied
to the cells in the presence of 8 μg/ml polybrene and stable cultures were selected in medium supplemented with
2 mg/mL G418. After doxycycline treatment (1 μg/mL; Sigma) for 48 h/72 h, the overexpression of EPHA3 (WT
or D806N mutant) was tested by FACS and western blot. Cells transfected with pLenti-CMV/TO (empty vector)
or pINDUCER20-GFP were used to control for possible non-specific effects of doxycycline treatment.
SW48 colon cancer cells show high levels of EPHA3 expression (Supplementary Figure 2A) and have
two mutant alleles of EPHA3 (K365Nfs*6 and G784E)18,27 that have also been observed in primary colorectal tumors48. A CRISPR/Cas9 approach was used to knockout both EPHA3 alleles in SW48 cells. The sgRNA
CTCTGTTCTCGACAGCTTCG was cloned into pSpCas9(BB)-2A-GFP (Addgene #48138). SW48 cells were
transiently transfected with pSpCas9(BB)-2A-GFP-sgEPHA3 using Lipofectamine 2000. GFP-positive cells
were sorted 48 h post-transfection and plated at low density. After two weeks, individual clones were expanded,
DNA extracted, the target region was PCR amplified (EPHA3-Ex1-F: CGG CCT CAT CAC ATC TTC TG and
EPHA3-Ex1-R: CTT CGG TGA GAA CGT GCT TT) and sequenced. Three clones with confirmed EPHA3 mutations and loss of EPHA3 expression as well as three EPHA3 wild type clones retaining EPHA3 expression were
selected.
Clinical samples. Samples from colorectal cancer patients with locally advanced disease (Dukes C) were
collected at nine hospitals from Finland and informed consent for genetic analysis of the tumor sample was
provided by each patient as previously described49,50. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the appropriate ethics review
committees as described49,50. The mean follow up of these patients was 7.3 years (range from 3.1 to 9.5 years).
For tissue microarray preparation, areas containing a high proportion of tumor cells were selected after histological examination of hematoxylin and eosin stained tumor sections. As previously described9,51, triplicate
0.6 mm cores from every sample were arrayed in a fresh paraffin block using a Beecher Instrument tissue arrayer
(Silver Spring, MD). Unstained 4 μm sections from the tissue microarray were mounted on slides coated with
3-aminopropyl-triethoxy-silane (Sigma, St Louis, MO).
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RNA extraction and quantitative RT-PCR. Total RNA was extracted from mouse liver and intestinal epithelial cells using TRI Reagent according to the manufacturer’s instructions (Molecular Research
Center). The RNA (500 ng) was reverse transcribed using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems), and relative Epha3 mRNA levels were assessed by Real-Time PCR (SYBR Green
Master Mix; Applied Biosystems, Branchburg, NJ). 18s rRNA (Taqman Master Mix) was used as a standardization control for the 2 −ΔΔCt method as described before 52. The primers used were Epha3-qPCR-F:
5′-CAGCCTTCCAACGAAGTTAAT 3′; Epha3-qPCR-R: 5′-CCATGGGATGGGTAGGAG-3′; 18 s rRNA-F:
5′-AGTCCCTGCCCTTTGTACACA -3′; 18 s rRNA-R: 5′-GATCCGAGGGCCTCACTAAAC-3′; 18s Probe:
5′-FAM-CGCCCGTCGCTACCGATTGG-TAMRA-3′.
Western blotting.

Cell cultures were harvested at 70% confluence and cell pellets resuspended in radioimmunoprecipitation (RIPA) assay buffer (0.1% SDS, 1% NP40 and 0.5% Na-deoxycholate in PBS) complemented
with protease inhibitors (Pepstatine 5 μg/μl, PMSF 0.3 mM, Aprotinine 1 μg/μl and Sodium orthovanadate 0.1 μ
M). Aliquots of total protein (100 μg) were loaded on 10% acrylamide gels. After gel electrophoresis, proteins
were transferred to a PVDF membrane and probed as described with rabbit anti-Epha3 (1:200; clone L18, Santa
Cruz), rabbit anti-EphrinA5 (1:500; Novus Biological), mouse anti-phospho-tyrosine (1:2000; clone PY20, BD
Transduction Laboratories) or mouse anti-β-Tubulin (1:2500; clone TUB 2.1; Sigma).

Xenograft and lung metastasis mouse models.

Twelve NOD/SCID mice (Harlan Laboratory)
7/8-week-old were injected subcutaneously with 2.8 ×  106 DLD1-EPHA3 cells (right flank) and the control
DLD1-EV cells (left flank) resuspended in 100 μl PBS. The animals were randomized in a group receiving doxycycline in the drinking water (1 mg/ml doxycycline and 2.5% sucrose, Sigma) or a control group (2.5% sucrose). The
same experimental set-up was carried out for LS174T-EPHA3 and the corresponding empty vector control cells
(2.8 ×  106cells). Tumor size was measured using a caliper three times per week. Tumor volume was calculated
with the formula: V =  (L ×  W2) × 0.5, where L is the length and W is the width of the xenograft. For the model
of experimental lung metastasis, LS174T-EPHA3 (3 ×  106 cells) or DLD1-EPHA3 (2 ×  106 cells) resuspended in
100 μl of PBS were injected in the lateral tail vein of NOD/SCID mice (Harlan Laboratory) 8/9-week-old. The
animals were randomized into a group receiving doxycycline in the drinking water (1 mg/ml doxycycline and
2.5% sucrose, Sigma) or a control group (2.5% sucrose) and sacrificed at the indicated time. The number of lung
metastatic foci was scored and then the lungs were formalin-fixed, paraffin-embedded, sectioned and stained
with hematoxylin and eosin. All animal experiments were carried out under protocols approved by the Vall d’Hebron Ethical Committee for Animal Experimentation and the appropriate governmental agency and carried out
in accordance with the approved guidelines.

Immunoprecipitation. Cells were lysed with RIPA buffer containing protease and phosphatase inhibitors
and briefly sonicated. Total protein (1 mg) was pre-incubated with mouse anti-EPHA3 (clone IIIA428; 1 μg per
1 mg of protein) in immunoprecipitation (IP) buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1.5 mM MgCl2, 1%
Triton X-100, 5% glycerol) at 4 °C overnight. Prewashed protein G-Agarose beads (Santa Cruz Biotechnology)
were added with further incubation for 1 h at 4 °C. Samples were then washed five times in IP buffer and analyzed
by western blotting with the indicated antibodies.
FACS analysis. Cell surface expression of EPHA3 (WT or D806N mutant) in LS174T and DLD1 engineered cell lines was confirmed by FACS. Cells (5 ×  105 per sample) pretreated with doxycycline for 48 h/72 h
were suspended in 100 μl of PBS with 5 μg/ml anti-EPHA3 (clone IIIA4) or anti-GAPDH (clone 6C5; Santa Cruz
Biotechnology) for 1 h. Cells were washed with cold PBS and incubated with FITC or CFL647-labeled secondary
antibodies specific for mouse IgG (114-096-062; Jackson Immuno Research Laboratories and sc-362287; Santa
Cruz Biotechnology, respectively). After incubation for 30 min at 4 °C, cells were again washed and resuspended
in PBS-propidium iodide solution (2 μg/ml). Fluorescence was quantified with a BD FACSCalibur instrument and
CellQuest Software (BD Biosciences).
Mouse knockout strains and azoxymethane treatment. Apcmin/+ mice on a 129/Sv background have

been described before53. These mice carry a heterozygous mutation in Apc inducing formation of multiple polyps
mainly in the small intestine21. The EphA3 knockout mouse has been previously described and is on a 129 ×  1/
SvJ genetic background19. The first exon of EPHA3, encoding its signal sequence, was removed and replaced
with a PGK-neo cassette by homologous recombination. Male Apcmin/+;EphA3+/+ mice were crossed with female
Apc+/+;EphA3−/− mice to obtain Apcmin/+;EphA3+/− males and Apc+/+;EphA3+/− females that were subsequently
crossed to obtain the experimental animals Apcmin/+;EphA3+/+, Apcmin/+;EphA3+/− and Apcmin/+;EphA3−/−. In addition, nine-week-old EphA3+/+ and EphA3−/− (both Apc+/+) mice were i.p. injected with the intestine-specific
carcinogen azoxymethane (AOM; 10 mg/kg; Sigma) weekly for 9 weeks and sacrificed 7 weeks after the last AOM
injection.

Histology and immunohistochemistry.

Eighty-six-week-old mice (EphA3+/+ and EphA3 −/−) or
forty-one-week-old mice (Apcmin/+;EphA3+/+, Apcmin/+;EphA3+/− and Apcmin/+;EphA3−/−) were sacrificed, the
small and large intestines were dissected, opened longitudinally and fixed with 4% formalin. Tumor size and
number were scored under a dissecting microscope (OLYMPUS SZH stereo-zoom microscope, magnification X7.5) before paraffin inclusion. The intestine was rolled longitudinally using the ‘Swiss roll’ technique54
and embedded in paraffin. For immunohistochemistry, the NovoLink polymer detection system (Novocastra
Laboratories) was used. Human EPHA3 immunostaining was carried out with a rabbit polyclonal anti-EPHA3
(1:200; Clone L18, Santa Cruz). EPHA3 staining levels were scored using a semiquantitative scale from 0 (absence
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of EPHA3 Immunostaining) to 3 (highest immunostaining). EPHA3 expression was evaluated blinded from the
clinical data. For Kaplan-Meyer plots, EPHA3 levels were dichotomized as low or high EPHA3 using an average
score cutoff value of 1.5. Importantly, no significant survival differences between high/low EPHA3 groups were
observed with any other possible cutoff value. EPHA3 was considered as a continuous variable for Cox multivariate regression analysis of prognostic factors for these patients (covariates: EPHA3 levels, histologic grade, sex, age,
and tumor location) as show in Supplementary Table 1.

Clonogenicity assay.

LS174T-EPHA3 or DLD1-EPHA3 cells and the corresponding empty vector control
cells were seeded (5 ×  102) into 6-well plates and allowed to attach overnight. The medium was then replaced with
complete medium with or without doxycycline (1 μg/ml) as indicated and cells allowed to grow for 10 days. Plates
were then stained with crystal violet 0.1% and the number of macroscopically visible colonies was scored blinded
from the sample identity. Three independent experiments were carried out in triplicate.

In vitro proliferation assay.

Cells were seeded into 24-well plates in triplicate and allowed to attach overnight (5 ×  105 for LS174T-EPHA3 or 3 ×  105 for DLD1-EPHA3 and the corresponding empty vector cells).
Doxycycline (1 μg/ml) was added as indicated. Cell counting was performed by cell trypsinization and staining
with trypan blue. Viable cells were counted using a hemocytometer at times 0, 24, 48, 72 and 96 h. Growth curves
presented are the average of three independent experiments carried out in triplicate.

Wound-healing assay.

Cells were seeded into 6-well plates (2 ×  106 cells per well) and allowed to grow
until they reached 90% confluence with or without doxycycline (1 μg/ml) as indicated. The cell monolayer was
scratched with a sterile micropipette tip and the wound region was allowed to heal by cell migration. The area
that remained clear of cells after 4, 8, 12, 24 and 48 h was quantified blinded from sample identity with Image J
(National Institutes of Health, NIH) and compared with the area of the wound at time zero. The average of three
independent experiments in triplicate is shown.

Matrigel invasion assay. The ability of cells to invade through matrigel-coated filters was determined
using a 24-well Boyden chamber (Beckton Dickinson; 8 μm pore size) covered with 100 μl of 1 mg/mL Matrigel
(Beckton Dickinson). Cells (6 ×  105 of LS174T-EPHA3 or 3 ×  105 of DLD1-EPHA3) were seeded in 100 μl of
RPMI medium containing 1% FBS in the upper compartment of the transwell. Where indicated doxycycline
(1 μg/ml) was added. The lower compartment was filled with RPMI medium (with or without doxycycline) containing 10% FBS, acting as an attractant. After incubation for 48 h at 37 °C in 5% CO2, the cells that did not penetrate the filter were wiped out with a cotton swab, and the cells that had invaded into the lower surface of the filter
were fixed and stained with 5% crystal violet. Filters were mounted on microscope slides to enable cell counting
under the microscope (10X) blinded from the sample identity. The total number of invading cells was determined
and the average of three independent experiments run in triplicate is shown.
Soft-agar colony formation assay.

LS174T-EPHA3 or DLD1-EPHA3 cells were resuspended (1 ×  105)
in complete RPMI medium containing 0.3% agar with or without doxycycline (1 μg/ml) and then plated into
6-well plates on top of 0.6% agar in RPMI medium. Cultures were maintained at 37 °C in a 5% CO2 incubator
for 2–3 weeks depending on the cell line. Fresh complete RPMI medium was added with or without doxycycline
(1 μg/ml) every 2–3 days. The colonies were stained with nitro blue tetrazolium chloride (1 mg/ml; Sigma) and
the number of macroscopically visible colonies was scored blinded from the sample identity. Three independent
experiments were carried out in triplicate.
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